Canntab Therapeutics Limited receives initial indication of patentability for immediate release cannabidiol formulation
Canntab Therapeutics Limited, the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, is pleased to announce that it has received an initial assessment from the Geneva-based International Preliminary Report on Patentability (“IPRP”) for its Immediate Release Cannabidiol Formulation (the “Immediate Release Formulation”). The IPRP has indicated a positive finding of patentability, meaning that, in their opinion, Canntab’s formulation is not only patentable but also novel, non-obvious and useful. National filings have already been completed in the United States and internationally, and the international application has now been completed in Canada and Australia.
Although the opinions of the IPRP are not binding, many patent offices, including Canada’s for example, often defer to the IPRP. In fact, the Canadian office of the IPRP was also the international searching authority in this particular case, which bodes well for an eventual Canadian patent grant.
This is a first and an important indication that our Immediate Release Cannabidiol Formulation is unique and patentable. It is our intention to build on this success as we continue to seek additional patents in Canada, United States and internationally. Our extensive portfolio of proprietary hard tablets is our core value proposition and we believe that we are well positioned to be the dominant player in hard tablet cannabinoid formulations world-wide,” states Jeff Renwick, co-founder and CEO of Canntab.
Canntab’s Extensive IP Portfolio – At the Core of Our Value Proposition
See our Patent Portfolio for related products –
WIPO´s Patent Database Click here
USPTO Patent database:
Ordering viagra generico uk is the best way to enjoy positive results within a short time. In the stage of veins formed, is observed “columns” of dilated free viagra tablet vein, with winding path, which originally appeared in the upper leg. Chewable pills are not required to be gulped with water an hour or 40 minutes prior to having sex with your partner as in important site cheapest levitra this course of time of being together, unresolved problems between them is another big factor that they lose interest of having time for “bed”. * Ailments and chronic conditions such as hypertension, physical inactivity, or diabetes, with a risk serious chronic illness and death is huge. One should viagra wholesale check a store’s payment gateway and its privacy policy.
Cannadian Patent Database:
| # |
Patent # |
Patent Title |
Score |
| 1. |
3036585 |
SUSTAINED RELEASE CANNABINOID FORMULATIONS |
100% |
| 2. |
3050150 |
IMMEDIATE RELEASE CANNABIDIOL FORMULATIONS |
94% |
| 3. |
3005889 |
SUSTAINED RELEASE CANNABINOID FORMULATIONS |
94% |
| 4. |
3005885 |
SUSTAINED RELEASE CANNABINOID PELLETS |
94% |
| |
|
Ctr |
PubDate |
| Appl.No |
Applicant |
Inventor |
Int.Class |
| 1. 20180250262 |
SUSTAINED RELEASE CANNABINOID FORMULATIONS |
US |
06.09.2018 |
| 15898216 |
CannTab Therapeutics Limited |
Jeff Renwick |
A61K 31/352 |
| The present invention provides modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients. More specifically, the invention relates to modified release pharmaceutical compositions comprising delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), and a process for preparation thereof. The present invention also provides large scale batches of modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients. |
|
|
|
|
|
|
| 2. 20180214412 |
IMMEDIATE RELEASE CANNABINOID FORMULATIONS |
US |
02.08.2018 |
| 15878396 |
CannTab Therapeutics Limited |
Jeff Renwick |
A61K 31/353 |
| The present invention relates to immediate release pharmaceutical compositions comprising one or more natural or synthetic cannabinoids, and one or more pharmaceutically acceptable excipients. More specifically, the invention relates to immediate release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. |
|
|
|
|
|
|
| 3. 3005885 |
SUSTAINED RELEASE CANNABINOID PELLETS |
CA |
28.02.2019 |
| 3005885 |
CANNTAB THERAPEUTICS, LIMITED |
|
A61K 9/16 |
The present invention provides modified release pharmaceutical composition
comprising one or more natural or synthetic cannabinoids and one or more
pharmaceutically acceptable excipients. More specifically, the invention
relates to
modified release pharmaceutical compositions comprising cannabinoids and a
process for preparation thereof. The present invention also provides large
scale
batches of modified release pharmaceutical composition comprising one or more
natural or synthetic cannabinoids and one or more pharmaceutically acceptable
excipients. |
|
|
|
|
|
|
| 4. 3036585 |
SUSTAINED RELEASE CANNABINOID FORMULATIONS |
CA |
05.04.2018 |
| 3036585 |
CANNTAB THERAPEUTICS LIMITED |
|
A61K 47/44 |
| The present invention provides modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients. More specifically, the invention relates to modified release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. The present invention also provides large scale batches of modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients. |
|
|
|
|
|
|
| 5. 2017334283 |
Sustained release cannabinoid formulations |
AU |
05.04.2018 |
| 2017334283 |
Canntab Therapeutics Limited |
|
C07D 311/80 |
| The present invention provides modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients. More specifically, the invention relates to modified release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. The present invention also provides large scale batches of modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients. |
|
|
|
|
|
|
| 6. 20180085308 |
SUSTAINED RELEASE CANNABINOID FORMULATIONS |
US |
29.03.2018 |
| 15717026 |
CannTab Therapeutics Limited |
Jeff Renwick |
A61K 9/00 |
| The present invention provides modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients. More specifically, the invention relates to modified release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. The present invention also provides large scale batches of modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients. |
|
|
|
|
|
|
| 7. 20180263913 |
Modified Release Multi-Layer Tablet Cannabinoid Formulations |
US |
20.09.2018 |
| 15921651 |
CannTab Therapeutics, Limited |
Robert Scott Lefler |
A61K 9/24 |
| The present invention provides modified release pharmaceutical compositions, and methods for administering the compositions to a user, including humans. The composition may contain a combination of ingredients in proportions calculated to achieve therapeutic effect, including at least the following ingredients: one or more natural or synthetic cannabinoids, one or more release modifying agent(s), and one or more pharmaceutically acceptable excipient(s). The composition may be in a multi-layered solid dosage form to provide fast, controlled and also sustained release of specific ingredients. More specifically, the invention relates to modified release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. More specifically, the invention may control drug release in accordance with the therapeutic purpose and pharmacological properties of active substances. |
|
|
|
|
|
|
| 8. 20180263953 |
Sustained Release Cannabinoid Formulations |
US |
20.09.2018 |
| 15923066 |
CannTab Therapeutics, Limited |
Jeff Scott Renwick |
A61K 31/352 |
| The present invention provides modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients. More specifically, the invention relates to modified release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. The present invention also provides large scale batches of modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients. |
|
|
|
|
|
|
| 9. 3005889 |
SUSTAINED RELEASE CANNABINOID FORMULATIONS |
CA |
28.02.2019 |
| 3005889 |
CANNTAB THERAPEUTICS, LIMITED |
|
A61K 9/00 |
The present invention provides modified release pharmaceutical composition
comprising one or more natural or synthetic cannabinoids and one or more
pharmaceutically acceptable excipients. More specifically, the invention
relates to
modified release pharmaceutical compositions comprising cannabinoids and a
process for preparation thereof. The present invention also provides large
scale
batches of modified release pharmaceutical composition comprising one or more
natural or synthetic cannabinoids and one or more pharmaceutically acceptable
excipients. |
|
|
|
|
|
|
| 10. 2018210690 |
Immediate release cannabidiol formulations |
AU |
26.07.2018 |
| 2018210690 |
Canntab Therapeutics Limited |
|
C07D 311/80 |
| The present invention relates to immediate release pharmaceutical compositions comprising one or more natural or synthetic cannabinoids, and one or more pharmaceutically acceptable excipients. More specifically, the invention relates to immediate release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. |
|
|
|
|
|
|
|
|
|
|
|
|
Parte inferior do formulário
Parte superior do formulário
Results 1-10 of 18 for Criteria:FP:(Canntab Therapeutics) Office(s):all Language:pt Stemming: false
Page: / 2 Go
Parte inferior do formulário
Canntab is a drug pharmaceutical company that has successfully created a line of patent-pending precision oral delivery hard tablets. Canntab’s proprietary technology and know-how enables it to convert THC and CBD oil into a nano-emulsified granulation, and ultimately into a hard pill format.
Canntab has filed 13 patents in Canada and United States that cover a range of processes and formulations it needs to create its precision oral delivery hard tablets, the future of medical cannabis. These patents include Canntab’s proprietary nano-emulsification technology, granulation process, methods of manufacturing, and covers it’s full line of precision oral delivery hard tablets including; Instant (Immediate) Release Tablets, Extended Release Tablets, Sustained Release Tablets, Bi-Layered (Modified Release) Tablets and Flash Melt Formulations.
As a late stage applicant to be a non-growing Licensed Producer and Processor, Canntab will be able to leverage its growing IP portfolio at its completed manufacturing facilities in both Markham and Cobourg.
About Canntab Therapeutics Limited
Source: Company Press Release
Key Facts
-
- News CategoryIntellectual Property
- CompanyCanntab Therapeutics Ltd
- CountryAsia-Pacific > Australia
North America > Canada
Related
